<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004868</url>
  </required_header>
  <id_info>
    <org_study_id>NABTC-9902</org_study_id>
    <secondary_id>CDR0000067527</secondary_id>
    <secondary_id>MSKCC-01045</secondary_id>
    <secondary_id>NCI-00-C-0173</secondary_id>
    <nct_id>NCT00004868</nct_id>
    <nct_alias>NCT00006067</nct_alias>
  </id_info>
  <brief_title>SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy</brief_title>
  <official_title>A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the&#xD;
      tumor.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have&#xD;
      recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Phase I:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of SU5416 in patients with recurrent malignant&#xD;
           glioma who are, as well as those who are not, taking enzyme-inducing antiepileptic&#xD;
           drugs.&#xD;
&#xD;
        -  Determine the toxic effects (safety profile) of this drug in this patient population.&#xD;
&#xD;
        -  Characterize the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Develop exploratory data relative to surrogate endpoints of angiogenic activity in vivo,&#xD;
           including functional imaging and in vitro assays of endothelial cell inhibition and&#xD;
           serum angiogenic peptides.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
        -  Determine the efficacy of SU5416, in terms of 6-month progression-free survival, in&#xD;
           patients with recurrent high-grade glioma.&#xD;
&#xD;
        -  Determine, further, the safety profile of the phase II dose of this drug in this patient&#xD;
           population.&#xD;
&#xD;
        -  Develop exploratory data relative to surrogate endpoints of angiogenic activity in vivo&#xD;
           including functional imaging and in vitro assays of endothelial cell inhibition and&#xD;
           serum angiogenic peptides.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      concurrent enzyme-inducing antiepileptic drugs (no vs yes).&#xD;
&#xD;
      Patients receive SU5416 IV on days 1 and 4 weekly for 4 weeks. Courses repeat every 4 weeks&#xD;
      in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD has been determined, additional&#xD;
      patients are accrued to the phase II portion of the study. These patients receive SU5416 IV,&#xD;
      as in the phase I portion, at the appropriate MTD established in phase I.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 30 patients will be accrued for the phase I dose-escalation&#xD;
      portion of this study within 10 months. An additional 48 patients (32 with glioblastoma&#xD;
      multiforme and 16 with anaplastic glioma) will be accrued for the phase II portion of this&#xD;
      study within 6-8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2000</start_date>
  <completion_date type="Actual">September 15, 2005</completion_date>
  <primary_completion_date type="Actual">September 15, 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaxanib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven supratentorial malignant primary glioma, including:&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic mixed oligoastrocytoma&#xD;
&#xD;
               -  Malignant astrocytoma not otherwise specified&#xD;
&#xD;
               -  Benign or malignant meningiomas, including brain and spinal meningiomas&#xD;
&#xD;
          -  Patients with meningiomas are excluded from phase II portion of study&#xD;
&#xD;
          -  Must have shown unequivocal evidence of tumor recurrence or progression by CT scan or&#xD;
             MRI&#xD;
&#xD;
          -  Must have failed prior radiotherapy&#xD;
&#xD;
          -  Must have prestudy contrast MRI or contrast CT scan of brain on stable steroid dose&#xD;
             within the past 14 days&#xD;
&#xD;
               -  Must be on stable (unchanged) dose of steroids for at least 5 days before scans&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  Must have completed radiotherapy at least 2 months prior to enrollment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,300/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT less than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  No significant active hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No significant active renal disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncompensated coronary artery disease on ECG or physical examination&#xD;
&#xD;
          -  No history of myocardial infarction or severe/unstable angina within the past 6 months&#xD;
&#xD;
          -  No deep venous or arterial thrombosis within the past 3 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
&#xD;
          -  No other serious concurrent illness&#xD;
&#xD;
          -  No significant active psychiatric disease&#xD;
&#xD;
          -  No diabetes mellitus with severe peripheral vascular disease&#xD;
&#xD;
          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No serious active infection&#xD;
&#xD;
          -  No other concurrent disease that would obscure toxic effects or dangerously alter drug&#xD;
             metabolism&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy (e.g., interferon) and recovered&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Phase I:&#xD;
&#xD;
               -  No more than 2 prior chemotherapy regimens for recurrent disease&#xD;
&#xD;
          -  Phase II:&#xD;
&#xD;
               -  No more than 1 prior chemotherapy regimen for recurrent disease&#xD;
&#xD;
          -  At least 2 weeks since prior vincristine&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  At least 3 weeks since prior procarbazine&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy (e.g., tamoxifen) and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  Recent prior resection of recurrent or progressive tumor allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard A. Fine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Neuro-Oncology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>May 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2003</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Semaxinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

